Dr. Reddy’s Laboratories Ltd ADR (RDY)

Nov 7, 2026

Dr Reddy’s Laboratories Ltd has secured marketing authorization from Brazil’s ANVISA for its generic semaglutide injection, intended for adults with inadequately controlled type 2 diabetes mellitus. This approval allows the product to be used as an adjunct to diet and exercise, either as monotherapy or in combination with other diabetes medications. The company plans to launch the product in Brazil in partnership with Aché, tapping into a significant market where 16.6 million adults are affected by diabetes.

Nov 5, 2026

Dr. Reddy's Laboratories Ltd. has received Brazilian marketing authorization (ANVISA) for a once-weekly generic semaglutide injection to treat type 2 diabetes. The approval covers 2 mg/1.5 mL and 4 mg/3 mL multi-dose pens, opening access to Brazil's diabetes semaglutide market, estimated at US$24.46 crore for MAT September 2026. The company plans to launch the product with local partner Aché to address the 16.6 million adults living with diabetes in Brazil.

Nov 5, 2026

Indian drugmaker Dr Reddy's Laboratories has received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's diabetes drug Ozempic. Brazil has a significant population of adults living with diabetes, making this a key market. Dr Reddy's plans to relaunch generic semaglutide in Canada this quarter and target launches in Latin America and Africa in the coming months.

Nov 5, 2026

Dr Reddy's Laboratories has received marketing authorization from Brazil's drug regulator, ANVISA, for its generic semaglutide injection. This injection is used for treating adults with insufficiently controlled type 2 diabetes and will be available as a pre-filled, multi-dose injectable pen. The company plans to launch the product in Brazil, a market with a significant burden of diabetes, in collaboration with Aché.

Nov 3, 2026

Dr Reddy's Laboratories has received a tentative approval from the USFDA for the world's first generic HIV preventive injectable. This drug will be made available at $40 per year in 120 countries outside the United States, through a voluntary license from Gilead Sciences.

Nov 2, 2026

Dr Reddy’s Laboratories has received tentative approval from the USFDA for its twice-yearly injectable lenacapavir for HIV prevention. This approval, granted under the PEPFAR program, will enable the drug's availability across 120 countries under a voluntary licensing agreement with Gilead Sciences, priced at $40 per person per year. The first supplies are expected before the end of 2026, with broader availability in 2027, significantly accelerating access to this groundbreaking prevention option in low- and middle-income countries.

Nov 2, 2026

Dr Reddy’s Laboratories has received tentative approval from the US FDA for its generic lenacapavir, a twice-yearly injectable drug for HIV prevention. This approval, granted under the PEPFAR programme and a voluntary licensing agreement with Gilead Sciences, is expected to make the drug affordably accessible across 120 countries outside the US, with the first supplies anticipated before the end of 2026. The drug offers a less frequent alternative to current daily HIV prevention options, potentially improving adherence in low- and middle-income countries.

Nov 2, 2026

Shares of Dr. Reddy's Laboratories Ltd. fell 0.74% on Monday to 1,340.25 Indian rupees, underperforming the broader BSE SENSEX Index, which rose 1.66%. The company's stock closed 5.24% below its 52-week high achieved on June 29th.

Oct 28, 2026

Dr. Reddy's Laboratories Ltd. (500124) shares rose 2.33% to 1,335.40 Indian rupees on Wednesday, outperforming the broader market as the BSE SENSEX Index fell 0.48%. The company's stock closed 5.59% below its 52-week high.